Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study

INTRODUCTION: The presence or absence of cirrhosis in patients with chronic hepatitis C virus (HCV) infection influences the type and duration of antiviral therapy. Non-invasive markers, like serum aspartate aminotransferase (AST) to platelet ratio index (APRI), may help identify appropriate HCV tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Fontana, Robert J., Lens, Sabela, McPherson, Stuart, Elkhashab, Magdy, Ankoma-Sey, Victor, Bondin, Mark, dos Santos, Ana Gabriela Pires, Xue, Zhenyi, Trinh, Roger, Porcalla, Ariel, Zeuzem, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6860464/
https://www.ncbi.nlm.nih.gov/pubmed/31646465
http://dx.doi.org/10.1007/s12325-019-01123-0

Ejemplares similares

Ejemplares similares